Randomized clinical trial of intradermal suture and metallic stapling for incisional groin closure after vascular surgery (VASC-INF trial)
Por:
González-Sagredo, A, Olaria, MG, D'Oria, M, Lopez-García, P, Grando, B, Villanueva, BG, Garcia, EE, Carnaval, T, Llagostera, S, Lepidi, S, Vila, R, Iborra, E and Videla, S
Publicada:
1 nov 2025
Resumen:
Background Surgical-site infection (SSI) is a relevant complication in vascular surgery due to its associated morbidity and mortality. However, the optimal type of skin closure (intradermal suture versus metallic staples) to minimize SSI rates has been scarcely studied. The aim of this study was to compare the incidence of SSI associated with intradermal suture versus metallic staples in patients undergoing arterial surgery through a groin femoral approach.Methods A multicentre, open-label, superiority RCT was conducted between April 2022 and January 2024 across three tertiary hospitals (two in Spain and one in Italy). The last-patient, last-visit date was 31 March 2024. Patients were randomized (1 : 1) to receive intradermal sutures (experimental group) or metallic staples (control group) via a computer-generated random sequence prepared by an independent researcher not involved in other aspects of the trial. The primary outcome was the 28-day cumulative incidence of SSI after elective revascularization procedures with inguinal vertical incisions with or without concomitant incisions, assessed per the definitions of the US Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network.Results In this trial, 112 patients were randomized to intradermal suture and 113 patients were randomized to metallic staples. SSIs occurred in eight patients in the intradermal suture group (cumulative incidence of 7.1% (95% c.i. 3.7% to 13.5%)) and six patients in the metallic staples group (cumulative incidence of 5.3% (95% c.i. 2.5% to 11.1%)). The relative risk (RR) of SSI was 1.4 (95% c.i. 0.5 to 3.8) times higher in the intradermal suture group, but the results were not statistically significant (P = 0.769). No additional SSIs occurred at 84 days after surgery, and the rates of lymphocele, haematoma, or lymphorrhoea did not differ significantly between groups.Conclusion Intradermal sutures were not superior to metallic staples in preventing SSIs in patients undergoing vascular surgery through a groin femoral approach.Registration number NCT05434182 (http://www.clinicaltrials.gov).
This is the second RCT to be published regarding skin closure and the prevention of surgical-site infection (SSI) in vascular surgery.
Filiaciones:
González-Sagredo, A:
Bellvitge Univ Hosp, Vasc Surg Dept, Lhospitalet de Llobregat 08097, Barcelona, Spain
Olaria, MG:
Germans Tries I Pujol Univ Hosp, Vasc Surg Dept, Barcelona, Spain
D'Oria, M:
Trieste Univ Hosp, Cardiothoraco Vasc Dept, Div Vasc & Endovascular Surg, Trieste, Italy
Lopez-García, P:
Bellvitge Univ Hosp, Vasc Surg Dept, Lhospitalet de Llobregat 08097, Barcelona, Spain
Grando, B:
Trieste Univ Hosp, Cardiothoraco Vasc Dept, Div Vasc & Endovascular Surg, Trieste, Italy
Villanueva, BG:
Bellvitge Univ Hosp, Vasc Surg Dept, Lhospitalet de Llobregat 08097, Barcelona, Spain
Bellvitge Biomed Res Inst IDIBELL, Cardiovasc Dis Res Grp, Lhospitalet de Llobregat, Barcelona, Spain
Garcia, EE:
Bellvitge Univ Hosp, Vasc Surg Dept, Lhospitalet de Llobregat 08097, Barcelona, Spain
Bellvitge Biomed Res Inst IDIBELL, Cardiovasc Dis Res Grp, Lhospitalet de Llobregat, Barcelona, Spain
Carnaval, T:
Univ Barcelona, Sch Med & Hlth Sci, Dept Pathol & Expt Therapeut, Inst Neurosci,Pharmacol Unit, Lhospitalet de Llobregat, Spain
Bellvitge Biomed Res Inst, Neurosci Program, Neuropharmacol & Pain Grp, Lhospitalet de Llobregat, Barcelona, Spain
:
Germans Tries I Pujol Univ Hosp, Vasc Surg Dept, Barcelona, Spain
Lepidi, S:
Trieste Univ Hosp, Cardiothoraco Vasc Dept, Div Vasc & Endovascular Surg, Trieste, Italy
Vila, R:
Bellvitge Univ Hosp, Vasc Surg Dept, Lhospitalet de Llobregat 08097, Barcelona, Spain
Iborra, E:
Bellvitge Univ Hosp, Vasc Surg Dept, Lhospitalet de Llobregat 08097, Barcelona, Spain
Bellvitge Biomed Res Inst IDIBELL, Cardiovasc Dis Res Grp, Lhospitalet de Llobregat, Barcelona, Spain
Univ Barcelona, Sch Med, Dept Clin Sci, Barcelona, Spain
Videla, S:
Univ Barcelona, Sch Med & Hlth Sci, Dept Pathol & Expt Therapeut, Inst Neurosci,Pharmacol Unit, Lhospitalet de Llobregat, Spain
Bellvitge Biomed Res Inst, Neurosci Program, Neuropharmacol & Pain Grp, Lhospitalet de Llobregat, Barcelona, Spain
Germans Trias I Pujol Univ Hosp, Clin Pharmacol Dept, Clin Res Support Area, Badalona, Spain
|